glp-1 and graves disease Glucagon-like peptide 1 receptor agonist use risk of thyroid cancer: Scandinavian cohort study Dual Glucagon-Like Peptide-1 (GLP-1) and
Description
Nature 2020;577:4326.PubMed 47
Specific to cardiovascular-related death, ELIXA and SUSTAIN-6 trials showed similar performance relative to the placebo [ HR = 0.98 (95% CI 0.781.22) and HR = 0.98 (95% CI 0.651.48), respectively]
GIP, glucose-dependent insulin-stimulating peptide
We then plotted the cumulative medication cost over time against the flat cost of each surgery, thus calculating "break-even points" (when medication costs equal surgery costs)
Your healthcare provider must also: Decide whether a GLP-1 medication is medically appropriate for you
